Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

LAG-3 inhibitor

DRUG CLASS:

LAG-3 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Melanoma	No biomarker	Melanoma	nivolumab/relatlimab-rmbw Sensitive: A1 - Approval nivolumab / relatlimab-rmbw Sensitive : A1	nivolumab/relatlimab-rmbw Sensitive: A1 - Approval nivolumab / relatlimab-rmbw Sensitive : A1
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	nivolumab/relatlimab-rmbw Sensitive: A1 - Approval nivolumab / relatlimab-rmbw Sensitive : A1	nivolumab/relatlimab-rmbw Sensitive: A1 - Approval nivolumab / relatlimab-rmbw Sensitive : A1
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	nivolumab/relatlimab-rmbw Sensitive: A2 - Guideline nivolumab / relatlimab-rmbw Sensitive : A2	nivolumab/relatlimab-rmbw Sensitive: A2 - Guideline nivolumab / relatlimab-rmbw Sensitive : A2
LAG3 expression	Melanoma	LAG3 expression	Melanoma	nivolumab/relatlimab-rmbw Sensitive: B - Late Trials nivolumab / relatlimab-rmbw Sensitive : B	nivolumab/relatlimab-rmbw Sensitive: B - Late Trials nivolumab / relatlimab-rmbw Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab-cmkb + MGD013 Sensitive: C2 – Inclusion Criteria margetuximab-cmkb + MGD013 Sensitive : C2	margetuximab-cmkb + MGD013 Sensitive: C2 – Inclusion Criteria margetuximab-cmkb + MGD013 Sensitive : C2
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	BMS-986016 Sensitive: C2 – Inclusion Criteria BMS-986016 Sensitive : C2	BMS-986016 Sensitive: C2 – Inclusion Criteria BMS-986016 Sensitive : C2
PD-L1 overexpression	Diffuse Large B Cell Lymphoma	PD-L1 overexpression	Diffuse Large B Cell Lymphoma	MGD013 Sensitive: C3 – Early Trials MGD013 Sensitive : C3	MGD013 Sensitive: C3 – Early Trials MGD013 Sensitive : C3
PD-1 overexpression	Diffuse Large B Cell Lymphoma	PD-1 overexpression	Diffuse Large B Cell Lymphoma	MGD013 Sensitive: C3 – Early Trials MGD013 Sensitive : C3	MGD013 Sensitive: C3 – Early Trials MGD013 Sensitive : C3
LAG3 overexpression	Diffuse Large B Cell Lymphoma	LAG3 overexpression	Diffuse Large B Cell Lymphoma	MGD013 Sensitive: C3 – Early Trials MGD013 Sensitive : C3	MGD013 Sensitive: C3 – Early Trials MGD013 Sensitive : C3
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	margetuximab-cmkb + MGD013 Sensitive: C3 – Early Trials margetuximab-cmkb + MGD013 Sensitive : C3	margetuximab-cmkb + MGD013 Sensitive: C3 – Early Trials margetuximab-cmkb + MGD013 Sensitive : C3
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials pembrolizumab + MK-4280 Sensitive : C3	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials pembrolizumab + MK-4280 Sensitive : C3
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	sintilimab + IBI110 Sensitive: C3 – Early Trials sintilimab + IBI110 Sensitive : C3	sintilimab + IBI110 Sensitive: C3 – Early Trials sintilimab + IBI110 Sensitive : C3